Stocks · News reference
Filed: 2026-08-12 AccNo: 0001213900-26-088061 Size: 279 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.
Read original at benzingaGuggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.
Read original at benzingaB. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
Read original at benzinga